JOHN B HENNEMAN III Insider Trading $NLNK LUMOS PHARMA, INC.

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for JOHN B HENNEMAN III.

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of JOHN B HENNEMAN III. JOHN B HENNEMAN III is Director in Anika Therapeutics, Inc. ($ANIK) and Chief Administrative Officer in NEWLINK GENETICS CORP ($NLNK) and EVP, Chief Financial Officer in NEWLINK GENETICS CORP ($NLNK) and Director in Accretive Health, Inc. ($AH) and Director in SeaSpine Holdings Corp ($SPNE) and in Aprea Therapeutics, Inc. ($APRE).

JOHN B HENNEMAN III in LUMOS PHARMA, INC.

Trading Symbol: NLNK
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN B HENNEMAN III: Chief Administrative Officer, EVP, Chief Financial Officer
Holdings: 55,052 shares
Current Value: $752,561
Latest Transaction: Oct 02 2018
$NLNK Market Capitalization: $408.17M
$NLNK Previous Close: $13.67

Last 4 weeks trend: HOLD
Last 3 months trend: HOLD

Latest Insider Trading Transactions of JOHN B HENNEMAN III in LUMOS PHARMA, INC.

	1 Week	2 Weeks	1 Month	3 Months	6 Months	1 Year	2 Years
No. of Purchases	0	0	0	0	0	0	0
Value of Purchases ($)	0	0	0	0	0	0	0
No. of Sales	0	0	0	0	0	0	0
Value of Sales ($)	0	0	0	0	0	0	0

Sentiment: All, ANIK, APRE, NLNK, AH, SPNE

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
Oct 02 2018	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	Chief Administrativ ...	Payment of Exercise	F	2.28	2,484	5,664	55,052	57.5 K to 55.1 K (-4.32 %)
Mar 13 2018	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Option Exercise	A	7.85	122,000	957,700	122,000
Jan 04 2018	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Payment of Exercise	F	10.06	1,323	13,309	57,536	58.9 K to 57.5 K (-2.25 %)
Jan 04 2018	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Payment of Exercise	F	8.47	164	1,389	58,859	59 K to 58.9 K (-0.28 %)
Oct 02 2017	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Payment of Exercise	F	10.18	2,789	28,392	56,544	59.3 K to 56.5 K (-4.70 %)
Jan 05 2017	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Option Exercise	A	10.55	137,500	1,450,625	137,500
Jan 05 2017	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Payment of Exercise	F	11.04	1,323	14,606	58,612	59.9 K to 58.6 K (-2.21 %)
Jan 05 2017	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Payment of Exercise	F	10.28	164	1,686	59,935	60.1 K to 59.9 K (-0.27 %)
Oct 04 2016	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Payment of Exercise	F	15.02	2,789	41,891	60,099	62.9 K to 60.1 K (-4.43 %)
Aug 11 2016	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Option Exercise	A	10.78	150,000	1,617,000	150,000
Jan 06 2016	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Option Exercise	A	34.73	46,351	1,609,770	46,351
Jan 06 2016	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Sell	S	35.74	175	6,255	62,316	62.5 K to 62.3 K (-0.28 %)
Jan 06 2016	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Grant	A	0.00	16,201	0	62,491	46.3 K to 62.5 K (+35.00 %)
Oct 05 2015	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Payment of Exercise	F	35.32	4,199	148,309	46,290	50.5 K to 46.3 K (-8.32 %)
May 14 2015	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Buy	P	37.30	3,000	111,900	50,489	47.5 K to 50.5 K (+6.32 %)
May 14 2015	NLNK	NEWLINK GENETICS C ...	HENNEMAN JOHN B III	EVP, Chief Financia ...	Gift	G	0.00	300	0	47,489	47.8 K to 47.5 K (-0.63 %)

Page: 1